title: Facial reversal reaction: a dermatological emergency.
authors.forename: Angelo V
authors.initials: AV
authors.lastname: Marzano
authors.forename: Diego
authors.initials: D
authors.lastname: Tosi
authors.forename: Marco
authors.initials: M
authors.lastname: Cusini
authors.forename: Enrico
authors.initials: E
authors.lastname: Nunzi
authors.forename: Cesare
authors.initials: C
authors.lastname: Massone
authors.forename: Carlo
authors.initials: C
authors.lastname: Crosti
mesh_terms: D000328:Adult; D015703:Antigens, CD / Q000276:immunology; D015214:Antigens, Differentiation, Myelomonocytic / Q000276:immunology; D001402:B-Lymphocytes / Q000276:immunology; D017252:CD3 Complex / Q000276:immunology; D002991:Clofazimine / Q000627:therapeutic use; D003622:Dapsone / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D004630:Emergencies; D005145:Face / Q000294:innervation / Q000473:pathology; D005148:Facial Dermatoses / Q000188:drug therapy / Q000276:immunology / Q000473:pathology*; D006801:Humans; D007917:Leprostatic Agents / Q000627:therapeutic use; D015439:Leprosy, Borderline / Q000188:drug therapy / Q000276:immunology / Q000473:pathology*; D015441:Leprosy, Tuberculoid / Q000188:drug therapy / Q000276:immunology / Q000473:pathology*; D008297:Male; D011241:Prednisone / Q000627:therapeutic use; D011956:Receptors, Cell Surface / Q000276:immunology; D012293:Rifampin / Q000627:therapeutic use; D013601:T-Lymphocytes / Q000276:immunology; D016896:Treatment Outcome; D000098902:CD163 Antigen
chemical_list: D015703:Antigens, CD; D015214:Antigens, Differentiation, Myelomonocytic; D000098902:CD163 Antigen; D017252:CD3 Complex; D007917:Leprostatic Agents; D011956:Receptors, Cell Surface; D003622:Dapsone; D002991:Clofazimine; D011241:Prednisone; D012293:Rifampin